Evidence map›Paper›PMID 32342131›Full record

ArticleArchives of toxicology2020

Ex vivo/in vitro protective effect of myricetin bulk and nano-forms on PhIP-induced DNA damage in lymphocytes from healthy individuals and pre-cancerous MGUS patients.

Shabana Akhtar, Mojgan Najafzadeh, Mohammad Isreb, Lisa Newton, Rajendran C Gopalan, Diana Anderson

Open access · hybridAbstract read
In one paragraph

Article in Archives of toxicology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shabana AkhtarSchool of Chemistry and Biosciences, University of Bradford, Richmond Building, Bradford, BD7 1DP, UK.
Mojgan NajafzadehSchool of Chemistry and Biosciences, University of Bradford, Richmond Building, Bradford, BD7 1DP, UK.
Mohammad IsrebSchool of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.
Lisa NewtonBradford Royal Infirmary (BRI), Bradford, UK.
Rajendran C GopalanSchool of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.
Diana AndersonSchool of Chemistry and Biosciences, University of Bradford, Richmond Building, Bradford, BD7 1DP, UK. d.anderson1@bradford.ac.uk.
University of Bradford · GBBradford Royal Infirmary · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

2-Amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) is a central dietary mutagen, produced when proteinaceous food is heated at very high temperatures potentially causing DNA strand breaks. This study investigates the protective potential of a well-researched flavonoid, myricetin in its bulk and nano-forms against oxidative stress induced ex vivo/in vitro by PhIP in lymphocytes from pre-cancerous monoclonal gammopathy of undetermined significance (MGUS) patients and those from healthy individuals. The results from the Comet assay revealed that in the presence of myricetin bulk (10 µM) and myricetin nano (20 µM), the DNA damage caused by a high dose of PhIP (100 µM) was significantly (P < 0.001) reduced in both groups. However, nano has shown better protection in lymphocytes from pre-cancerous patients. Consistent results were obtained from the micronucleus assay where micronuclei frequency in binucleated cells significantly decreased upon supplementing PhIP with myricetin bulk (P < 0.01) and myricetin nano (P < 0.001), compared to the PhIP treatment alone. To briefly determine the cellular pathways involved in the protective role of myricetin against PhIP, we studied gene expression of P53 and ATR kinase (ATM- and Rad3-related), using the real-time PCR technique.

Indexed as

NanoparticlesAdultAgedAged, 80 and overAntimutagenic AgentsAntioxidantsAtaxia Telangiectasia Mutated ProteinsCase-Control StudiesCells, CulturedComet AssayDNA DamageFemaleFlavonoidsHumansImidazolesLymphocytes2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridineAntimutagenic AgentsAntioxidantsAtaxia Telangiectasia Mutated ProteinsATR protein, humanFlavonoidsImidazolesMutagensmyricetinTP53 protein, humanTumor Suppressor Protein p53ATRBulk and nano-formsLymphocytesMyricetinP53PhIPPre-cancerous patients

Identifiers

PMID32342131
PMCPMC7367907
OpenAlexW3018864341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.